ストックスクリーナーアプリを入手
35.89
1.14%
-0.415
アフターアワーズ：
36.78
0.89
+2.48%
Bridgebio Pharma Inc (BBIO) 最新ニュース
BridgeBio Pharma (BBIO) Set to Release Q1 Earnings Report - GuruFocus
BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: Wha - GuruFocus
A Look Ahead: BridgeBio Pharma's Earnings Forecast - Benzinga
Transthyretin Amyloid Cardiomyopathy Treatment Market Size - openPR.com
Pinning Down BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) P/S Is Difficult Right Now - simplywall.st
BridgeBio (BBIO) Gains UK Approval for Cardiomyopathy Drug | BBI - GuruFocus
BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis - marketscreener.com
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer - GuruFocus
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM - The Globe and Mail
BridgeBio Pharma Receives UK Approval for BEYONTTRA® (acoramidis) to Treat ATTR-CM - Nasdaq
UK Approves Groundbreaking ATTR-CM Drug BEYONTTRA with 42% Mortality Benefit | BBIO Stock News - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update - ADVFN
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - ADVFN
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) - PrimePublishers.com
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events - ADVFN
BridgeBio: Early Signs Point To Blockbuster Revenues - Seeking Alpha
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET | BBIO Stock News - GuruFocus
BridgeBio Pharma, Inc. to Report First Quarter Financial Results and Program Updates on April 29, 2025 - Nasdaq
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET - TradingView
BridgeBio Sets Q1 2025 Earnings Call: Key Genetic Disease Pipeline Updates Expected April 29 - Stock Titan
BridgeBio Pharma director Ellis sells $350,000 in stock By Investing.com - Investing.com India
BridgeBio Pharma director Ellis sells $350,000 in stock - Investing.com Australia
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
BridgeBio (BBIO) Receives Increased Price Target from H.C. Wainw - GuruFocus
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BBIO Stock News - GuruFocus
BridgeBio Pharma (BBIO) Sees Promising Growth Amid Market Volati - GuruFocus
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Expands Team: Strategic Equity Grants Awarded to 20 New Hires - Stock Titan
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Praxis Precision Medicines (PRAX) - The Globe and Mail
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma director Andrea Ellis sells $1.02 million in stock - Investing.com India
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (MUN:2CL) with Buy Recommendation - Nasdaq
Raymond James maintains $57 target on BridgeBio stock By Investing.com - Investing.com Canada
Revolutionary Dual-State KRAS Inhibitor Enters Clinical Trials for Advanced Cancer Treatment - Stock Titan
BBOT Announces First Patient Dosed with BBO-11818, a PanKRAS Dual Inhibitor in the Phase 1 KONQUER-101 Trial for Advanced Solid Tumors - Business Wire
Acoramidis shows promise in ATTR-CM Phase 3 trial By Investing.com - Investing.com South Africa
Redburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - Nasdaq
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial - MarketScreener
Acoramidis shows promise in ATTR-CM Phase 3 trial - Investing.com
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM - Yahoo Finance
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target - MarketScreener
Redburn-Atlantic sets $50 target for BridgeBio stock with Buy rating - Investing.com India
Pictet Asset Management Holding SA Sells 995,585 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Cytokinetics, Madrigal, and BridgeBio Emerge as Potential Pharma Takeover Targets - GuruFocus
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
(BBIO) Technical Data - news.stocktradersdaily.com
Genmab and BridgeBio Pharma announce Japan approval for their treatments - MSN
BridgeBio Pharma CEO sells $2.76 million in stock By Investing.com - Investing.com Canada
BridgeBio Pharma CEO sells $2.76 million in stock - Investing.com India
Japan approves new ATTR-CM treatment Beyonttra By Investing.com - Investing.com South Africa
Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga
BridgeBio’s Beyonttra approved in Japan - The Pharma Letter
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition - Marketscreener.com
BridgeBio Announces Approval Of Beyonttra In Japan; To Receive $30 Mln Milestone Payment - Nasdaq
0.19%
大文字化:
|
ボリューム (24 時間):